Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Lifted by Jacobi Capital Management LLC

Jacobi Capital Management LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,139 shares of the biopharmaceutical company’s stock after purchasing an additional 20 shares during the period. Jacobi Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,096,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after acquiring an additional 91,956 shares in the last quarter. Capital World Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares in the last quarter. Putnam Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $932,571,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock valued at $545,081,000 after acquiring an additional 22,558 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of REGN traded up $6.14 during mid-day trading on Monday, hitting $1,069.74. 299,549 shares of the company’s stock were exchanged, compared to its average volume of 469,325. The firm has a fifty day moving average of $1,025.07 and a two-hundred day moving average of $972.23. Regeneron Pharmaceuticals, Inc. has a twelve month low of $721.51 and a twelve month high of $1,106.16. The stock has a market cap of $117.87 billion, a price-to-earnings ratio of 31.50, a P/E/G ratio of 2.20 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,067.23.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.